Annual Current Assets
$14.93 M
+$1.23 M+8.99%
December 31, 2023
Summary
- As of February 8, 2025, EPRX annual total current assets is $14.93 million, with the most recent change of +$1.23 million (+8.99%) on December 31, 2023.
- During the last 3 years, EPRX annual current assets has risen by +$14.04 million (+1572.38%).
- EPRX annual current assets is now -37.80% below its all-time high of $24.00 million, reached on December 1, 2021.
Performance
EPRX Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Assets
$9.89 M
-$14.64 M-59.67%
September 1, 2024
Summary
- As of February 8, 2025, EPRX quarterly total current assets is $9.89 million, with the most recent change of -$14.64 million (-59.67%) on September 1, 2024.
- Over the past year, EPRX quarterly current assets has dropped by -$14.64 million (-59.67%).
- EPRX quarterly current assets is now -72.69% below its all-time high of $36.22 million, reached on March 31, 2024.
Performance
EPRX Quarterly Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Assets Formula
Current Assets = Cash and Equivalents + Accounts Receivable + Inventory + Prepaid Expenses + Marketable Securities + Other Current Assets
EPRX Current Assets Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +9.0% | -59.7% |
3 y3 years | +1572.4% | -58.8% |
5 y5 years | +721.9% | - |
EPRX Current Assets Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -37.8% | +9.0% | -72.7% | at low |
5 y | 5-year | -37.8% | +1572.4% | -72.7% | +2170.4% |
alltime | all time | -37.8% | +1572.4% | -72.7% | +2170.4% |
Eupraxia Pharmaceuticals Current Assets History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $9.89 M(-59.7%) |
Jun 2024 | - | $24.53 M(-32.3%) |
Mar 2024 | - | $36.22 M(+82.9%) |
Dec 2023 | $349.10 K(-11.1%) | $19.80 M(-20.3%) |
Sep 2023 | - | $24.85 M(+66.8%) |
Jun 2023 | - | $14.89 M(-19.9%) |
Dec 2022 | $392.90 K | - |
Dec 2022 | - | $18.59 M(-17.4%) |
Sep 2022 | - | $22.51 M(-20.3%) |
Jun 2022 | - | $28.25 M(+32.4%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $21.34 M(-11.1%) |
Dec 2021 | $486.60 K(+96.8%) | $24.00 M(-10.6%) |
Sep 2021 | - | $26.84 M(-9.7%) |
Jun 2021 | - | $29.73 M(+16.3%) |
Mar 2021 | - | $25.56 M(+2763.3%) |
Dec 2020 | $247.30 K(-50.0%) | $892.60 K(+104.9%) |
Sep 2020 | - | $435.60 K(-78.4%) |
Dec 2019 | $494.70 K(+54.7%) | $2.02 M |
Dec 2018 | $319.70 K(-4.2%) | - |
Dec 2017 | $333.60 K | - |
FAQ
- What is Eupraxia Pharmaceuticals annual total current assets?
- What is the all time high annual current assets for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals annual current assets year-on-year change?
- What is Eupraxia Pharmaceuticals quarterly total current assets?
- What is the all time high quarterly current assets for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals quarterly current assets year-on-year change?
What is Eupraxia Pharmaceuticals annual total current assets?
The current annual current assets of EPRX is $14.93 M
What is the all time high annual current assets for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high annual total current assets is $24.00 M
What is Eupraxia Pharmaceuticals annual current assets year-on-year change?
Over the past year, EPRX annual total current assets has changed by +$1.23 M (+8.99%)
What is Eupraxia Pharmaceuticals quarterly total current assets?
The current quarterly current assets of EPRX is $9.89 M
What is the all time high quarterly current assets for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high quarterly total current assets is $36.22 M
What is Eupraxia Pharmaceuticals quarterly current assets year-on-year change?
Over the past year, EPRX quarterly total current assets has changed by -$14.64 M (-59.67%)